PCN83 Cost Effectiveness Analysis in the Veneto Region of Cabazitaxel Versus Mitoxantrone in Patients with Metastatic Hormone Refractory Prostate Cancer, Previously Treated With a Docetaxel Containing Regimen
Nov 1, 2012, 00:00 AM
10.1016/j.jval.2012.08.2123
https://www.valueinhealthjournal.com/article/S1098-3015(12)03837-5/fulltext
Section Title :
Cancer
Section Order :
778
First Page :
A424
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03837-5&doi=10.1016/j.jval.2012.08.2123